UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~May~~July 56, 2026

_______________

CONCENTRA GROUP HOLDINGS PARENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

_______________

001-42188

(Commission File Number)


Delaware			30-1006613
(State or Other Jurisdiction of Incorporation)			(I.R.S. Employer Identification No.)

5080 Spectrum Drive, Suite 1200W

Addison, TX, 75001

(Address of principal executive offices) (Zip code)

(972) 364-8000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value per share

CON

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

OnConsulting May 7, 2026, Concentra Group Holdings Parent, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2026. A copy of the press release and financial schedules are attached as Exhibit 99.1 to this report and incorporated herein by reference.Agreement

~~The~~As ~~information~~previously indisclosed, ~~this~~on ~~report~~April ~~(including~~10, ~~Exhibit~~2026, 99Dr.1) isJohn ~~being furnished pursuant to Item 2~~R.02 ~~and~~Anderson ~~shall~~notified ~~not~~Concentra beGroup ~~deemed~~Holdings ~~to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934~~Parent, asInc. ~~amended~~ (the “~~Exchange Act~~Company”), ~~or otherwise subject to the liabilities~~ of ~~that~~his ~~section,~~retirement ~~nor~~from ~~shall~~his itposition beas ~~deemed~~Executive toVice bePresident ~~incorporated~~and byChief ~~reference~~Medical inOfficer ~~any~~of ~~filing under~~ the ~~Securities~~Company ~~Act~~effective ~~of 1933,~~ as ~~amended~~of ~~(the~~December ~~“Securities Act”)~~31, ~~or the Exchange Act~~2026.

~~Item~~In 7connection with Dr.~~01 Regulation~~ FDAnderson’s ~~Disclosure~~retirement, on July 6, 2026, Concentra Health Services, Inc., a subsidiary of the Company (“Concentra”), and Dr. Anderson entered into a consulting agreement, pursuant to which Dr. Anderson will serve as an independent contractor providing part-time consulting services to Concentra following his retirement (the “Consulting Agreement”). The Consulting Agreement becomes effective on January 1, 2027 (the “Effective Date”) and has a term through December 31, 2027 (the “Term”), unless earlier terminated. Either party may terminate the Consulting Agreement at any time upon 30 days’ prior written notice to the other party. Concentra may terminate the Consulting Agreement immediately for Cause (as defined in Dr. Anderson’s Employment Agreement with Concentra dated November 19, 2010, as amended).

~~Attached~~Under asthe ~~Exhibit~~Consulting 99Agreement, Dr.2 ~~and~~Anderson ~~furnished~~will provide consulting services for ~~purposes~~up ofto ~~Regulation~~10 FDhours isper week at a ~~presentation~~rate ~~published~~of by$216.00 per hour in connection with clinical strategy, medical affairs, regulatory matters, and such other matters as may be reasonably requested. The Consulting Agreement provides that Dr. Anderson’s outstanding unvested restricted stock awards granted under the ~~Company~~Concentra onGroup ~~May 7~~Holdings Parent, ~~2026~~Inc. 2024 Equity Incentive Plan will continue to vest during the Term, inprovided ~~connection~~that ~~with~~Dr. ~~its~~Anderson ~~press~~continues ~~release~~to ~~announcing~~provide ~~its~~consulting ~~financial~~services ~~results~~through each applicable vesting date. If Dr. Anderson completes the full Term without being terminated for ~~its~~Cause ~~first~~or ~~quarter~~voluntarily ~~ended~~resigning, ~~March 31~~25% of Dr. Anderson’s then-unvested restricted stock will automatically vest. If Dr. Anderson is terminated for Cause or voluntarily resigns prior to the expiration of the Term, ~~2026~~all of Dr. Anderson’s unvested equity awards will be immediately forfeited. The equity benefits are subject to Dr. Anderson’s execution of a general release of claims upon the commencement of the Term and a final release upon the expiration or earlier termination of the Consulting Agreement.

The ~~information~~foregoing indescription ~~this~~of ~~Current~~the ~~Report~~Consulting onAgreement ~~Form~~does ~~8-K~~not ~~(including~~purport ~~Exhibit 99.2) is being furnished solely~~ to ~~satisfy~~be ~~the~~complete ~~requirements~~and ofis ~~Regulation~~qualified FDin ~~and~~its ~~shall~~entirety ~~not~~by bereference ~~deemed~~ to bethe ~~“filed”~~full ~~for~~text ~~purposes~~ of ~~Section 18 of~~ the ~~Exchange~~Consulting ~~Act~~Agreement, orwhich ~~otherwise~~is ~~subject~~filed toas ~~the~~Exhibit ~~liabilities~~10.1 ofto ~~that~~this ~~section,~~Current ~~nor~~Report ~~shall~~on itForm be8-K ~~deemed~~and tois be incorporated herein by reference ~~in any filing under the Securities Act or the Exchange Act~~.

Item 8.01 Other Events.

Dividend Declaration

On May 5, 2026, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about June 9, 2026, to stockholders of record as of the close of business on May 19, 2026.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press Release, dated May 7, 2026, announcing financial results for the first quarter ended March 31, 2026 and cash dividend.
10.1*			Consulting Agreement, dated as of July 6, 2026, by and between Concentra Health Services, Inc. and Dr. John Anderson.
99.2			Concentra Group Holdings Parent Inc. Presentation.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).


*			Indicates a management contract or compensatory plan or arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CONCENTRA GROUP HOLDINGS PARENT, INC.
Date: May 7, 2026	By:	/s/ Timothy Ryan
Date: July 10, 2026	By:	/s/ Timothy Ryan
		Timothy Ryan
		Executive Vice President and Chief Legal Counsel

Filing Compare · Concentra Group Holdings Parent, Inc.